Jubilant Life Sciences net up 21% in 2012-13

Integrated pharmaceutical and lifesciences company Jubilant Life Sciences (JLS) reported an 18% increase in income from the operations to R1,392 crore during the quarter ended March 31, 2013.

Integrated pharmaceutical and lifesciences company Jubilant Life Sciences (JLS) reported an 18% increase in income from the operations to Rs 1,392 crore during the quarter ended March 31, 2013.

HT Image

For the full year 2012-13, the company's total income grew 21% to Rs 5,161 crore, while profit after tax stood at Rs 153 crore, up from Rs 15 crore.

“The company has delivered strong growth momentum driven by generic and radiopharmaceutical businesses with new product launches and expansion in geographic outreach,” said Shyam S Bhartia, chairman and MD, and Hari S Bhartia, co-chairman and MD, JLS.